221 results on '"Altomonte, Jennifer"'
Search Results
2. Streamlining the purification of a clinical-grade oncolytic virus for therapeutic applications
3. Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
4. Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures
5. A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.
6. Author Correction: Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
7. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
8. Characterization of a quail suspension cell line for production of a fusogenic oncolytic virus
9. Supplementary Fig. S1 from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib
10. Supplementary tables S1-3 and figure legends from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib
11. Klinische und therapeutische Relevanz von viralen Onkogenen bei sinunasalen Plattenepithelkarzinomen.
12. Process intensification strategies toward cell culture‐based high‐yield production of a fusogenic oncolytic virus.
13. LIVER CANCER: Sensitizing hepatocellular carcinoma to oncolytic virus therapy
14. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy
15. Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
16. Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
17. Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
18. Author Correction: Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
19. Oncolytic Virotherapy with the Fusogenic VSV-NDV Platform Complementing Adoptive T Cell Therapy
20. Clinical Value and Limitations of [11C]-Methionine PET for Detection and Localization of Suspected Parathyroid Adenomas
21. Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat
22. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
23. PPAR[alpha] mediates the hypolipidemic action of fibrates by antagonizing FoxO1
24. Evaluation of hepatitis B virus surface protein variations in patients under therapy with nucleic acid polymer REP 2139-Ca
25. Evaluation of hepatitis B virus surface protein variations in patients under therapy with nucleic acid polymer REP 2139-Ca
26. Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
27. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice
28. Surgeon Yurii Voronoy (1895–1961) – a pioneer in the history of clinical transplantation: in Memoriam at the 75th Anniversary of the First Human Kidney Transplantation
29. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats
30. Aberrant Forkhead Box O1 Function Is Associated with Impaired Hepatic Metabolism
31. Increased Hepatic Levels of the Insulin Receptor Inhibitor, PC-1/NPP1, Induce Insulin Resistance and Glucose Intolerance
32. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
33. Elevated Vascular Endothelial Growth Factor Production in Islets Improves Islet Graft Vascularization
34. Improved Insulin Sensitivity Is Associated With Restricted Intake of Dietary Glycoxidation Products in the db/db Mouse
35. Basal Insulin Gene Expression Significantly Improves Conventional Insulin Therapy in Type 1 Diabetic Rats
36. Fat depot-specific expression of adiponectin is impaired in zucker fatty rats
37. Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers
38. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma
39. Fusogenic Viruses in Oncolytic Immunotherapy
40. Abstract B14: TCR transgenic T cells improve the anticancer potential of oncolytic vesicular stomatitis virus as cell carriers and as synergistic therapeutics
41. Fusogenic Viruses in Oncolytic Immunotherapy
42. Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses
43. Sensitizing hepatocellular carcinoma to oncolytic virus therapy
44. Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
45. Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
46. Optimization of Oncolytic Viral Therapy for Hepatocellular Carcinoma
47. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib
48. PET Imaging of Oncolytic VSV Expressing the Mutant HSV-1 Thymidine Kinase Transgene in a Preclinical HCC Rat Model
49. Characterization of Magnetic Viral Complexes for Targeted Delivery in Oncology
50. Exponential Enhancement of Oncolytic VSV Potency by Vector-Mediated Suppression of Inflammatory Responses In Vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.